157 related articles for article (PubMed ID: 20127735)
1. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
Eaton CL; Colombel M; van der Pluijm G; Cecchini M; Wetterwald A; Lippitt J; Rehman I; Hamdy F; Thalman G
Prostate; 2010 Jun; 70(8):875-82. PubMed ID: 20127735
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.
Colombel M; Eaton CL; Hamdy F; Ricci E; van der Pluijm G; Cecchini M; Mege-Lechevallier F; Clezardin P; Thalmann G
Prostate; 2012 May; 72(7):713-20. PubMed ID: 21882211
[TBL] [Abstract][Full Text] [Related]
5. Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.
Wang N; Docherty F; Brown HK; Reeves K; Fowles A; Lawson M; Ottewell PD; Holen I; Croucher PI; Eaton CL
FASEB J; 2015 Aug; 29(8):3141-50. PubMed ID: 25888599
[TBL] [Abstract][Full Text] [Related]
6. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
[TBL] [Abstract][Full Text] [Related]
7. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
8. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
9. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.
Guzmán-Ramírez N; Völler M; Wetterwald A; Germann M; Cross NA; Rentsch CA; Schalken J; Thalmann GN; Cecchini MG
Prostate; 2009 Nov; 69(15):1683-93. PubMed ID: 19644960
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma.
Liu J; Brown RE
Int J Clin Exp Pathol; 2010 Oct; 3(8):755-62. PubMed ID: 21151388
[TBL] [Abstract][Full Text] [Related]
11. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.
Yamamoto H; Masters JR; Dasgupta P; Chandra A; Popert R; Freeman A; Ahmed A
PLoS One; 2012; 7(10):e46979. PubMed ID: 23071686
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of katanin p60 in prostate cancer bone metastasis.
Ye X; Lee YC; Choueiri M; Chu K; Huang CF; Tsai WW; Kobayashi R; Logothetis CJ; Yu-Lee LY; Lin SH
Prostate; 2012 Feb; 72(3):291-300. PubMed ID: 21681775
[TBL] [Abstract][Full Text] [Related]
13. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.
Miki J; Furusato B; Li H; Gu Y; Takahashi H; Egawa S; Sesterhenn IA; McLeod DG; Srivastava S; Rhim JS
Cancer Res; 2007 Apr; 67(7):3153-61. PubMed ID: 17409422
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
15. [Isolation and characterization of brain tumor stem cells in human medulloblastoma].
Li MC; Deng YW; Wu J; Chen FH; Liu JF; Fang JS
Ai Zheng; 2006 Feb; 25(2):241-6. PubMed ID: 16480595
[TBL] [Abstract][Full Text] [Related]
16. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
17. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
18. Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer.
Costa CD; Justo AA; Kobayashi PE; Story MM; Palmieri C; Laufer Amorim R; Fonseca-Alves CE
Int J Biochem Cell Biol; 2019 Mar; 108():21-28. PubMed ID: 30633985
[TBL] [Abstract][Full Text] [Related]
19. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
[TBL] [Abstract][Full Text] [Related]
20. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells.
Fusi A; Reichelt U; Busse A; Ochsenreither S; Rietz A; Maisel M; Keilholz U
J Invest Dermatol; 2011 Feb; 131(2):487-94. PubMed ID: 20882037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
